000			01396 a2200421 4500
005			20250515035303.0
264		0	_c20061107
008			200611s 0 0 eng d
022			_a0887-6924
024	7		_a10.1038/sj.leu.2404349 _2doi
040			_aNLM _beng _cNLM
100	1		_aLhermitte, L
245	0	0	_aMost immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy. _h[electronic resource]
260			_bLeukemia _cOct 2006
300			_a1908-10 p. _bdigital
500			_aPublication Type: Letter; Research Support, Non-U.S. Gov't
650	0	4	_aCell Division
650	0	4	_aDiphtheria Toxin _xpharmacology
650	0	4	_aHumans
650	0	4	_aImmunophenotyping
650	0	4	_aInterleukin-3 _xpharmacology
650	0	4	_aInterleukin-3 Receptor alpha Subunit
650	0	4	_aLeukemia-Lymphoma, Adult T-Cell _xdrug therapy
650	0	4	_aReceptors, Interleukin-3 _xmetabolism
650	0	4	_aRecombinant Fusion Proteins _xpharmacology
700	1		_ade Labarthe, A
700	1		_aDupret, C
700	1		_aLapillonne, H
700	1		_aMillien, C
700	1		_aLandman-Parker, J
700	1		_aHermine, O
700	1		_aBaruchel, A
700	1		_aSigaux, F
700	1		_aMacintyre, E
700	1		_aAsnafi, V
773	0		_tLeukemia _gvol. 20 _gno. 10 _gp. 1908-10
856	4	0	_uhttps://doi.org/10.1038/sj.leu.2404349 _zAvailable from publisher's website
999			_c16487943 _d16487943